Login to Your Account



Phase III Starts Early Next Year

Intarcia Pumps Up with $210M for Once-Yearly Exenatide Bid

By Randy Osborne
Staff Writer

Monday, November 19, 2012
Privately held Intarcia Therapeutics Inc.'s subcutaneous, osmotic-pump method of delivering the glucagon-like peptide-1 receptor agonist exenatide will enter Phase III trials in the first quarter of next year, thanks to a whopping $210 million in new cash, gained through a pair of investments.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription